5Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions [ J ]. Clin Pharmacol Ther, 1981, 30(2) : 239-245.
6Tilelli JA, Smith KM, Pettignano R. Life-threatening bradyarrhythmia after massive azithromycin overdose[ J ]. Pharmacotherapy, 2006, 26(1) : 147-150.
7Kezerashvili A, Khattak H, Barsky A, et al. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors [ J ]. J Interv Card Eleetrophysiol, 2007, 18(3): 243-246.
8Volberg WA, Koci B J, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics[ J]. J Pharmacol Exp Ther, 2002, 302( 1 ) : 320-327.
9Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death[J]. N Engl J Med, 2012, 366(20) : 1881- 1890.
10U.S. Food and Drug Administration. FDA Drug Safety Communi- cation: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms [ EB/OL]. (2013-03-18) [ 2013- 04-15 ]. http://www, fda. gov/drugs/drugsafety/ucm341822. htm.
